A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride

CNS Neuroscience and Therapeutics

Volumn 14, Issue 3, 2008, Pages 248-262

  Martelle, Jennifer L ^a   Nader, Michael A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Behavioral pharmacology; Dopamine D2 like receptors; Eticlopride; Extrapyramidal side effects; Imaging

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; ETICLOPRIDE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE;

AUTORADIOGRAPHY; BEHAVIOR; BINDING AFFINITY; BLOOD DYSCRASIA; CLINICAL TRIAL; DOPAMINE RECEPTOR BLOCKING; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG USE; DRUG UTILIZATION; EX VIVO STUDY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LEARNING; MEMORY; NONHUMAN; PREDICTOR VARIABLE; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; PSYCHOSIS; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; SALICYLAMIDES; SIGNAL TRANSDUCTION;

EID: 49749141669     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00047.x     Document Type: Review

References (126)

1. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In : Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York : McGraw-Hill, 2006 461 500.
2. NIMH, National Institute of Mental Health (2008 What is schizophrenia http://www.nimh.nih.gov accessed 26 June 2008.
3. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993 50 : 85 94.
4. Dearry A, Gingrich JA, Falardeau P, Fremeau RT Jr., Bates MD, Caron MG. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990 347 : 72 76.
5. Mansour A, Meador-Woodruff JH, Zhou QY, Civelli O, Akil H, Watson SJ. A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience 1991 45 : 359 371.
6. Meador-Woodruff JH, Mansour A, Civelli O, Watson SJ. Distribution of D2 dopamine receptor mRNA in the primate brain. Prog Neuropsychopharmacol Biol Psychiatry 1991 15 : 885 893.
7. Monsma FJ Jr., Mahan LC, McVittie LD, Gerfen CR, Sibley DR. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci 1990 87 : 6723 6727.
8. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992 13 : 61 69.
9. 3H]raclopride. Proc Natl Acad Sci 1989 86 : 6412 6416.
10. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976 261 : 717 719.
11. Wong DF, Wagner HN Jr., Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986 234 : 1558 1563.
12. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird Ed, Riederer P, Jellinger K, Tourtellotte WW. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987 1 : 5 15.
13. Pickens RW. Behavioral pharmacology: A brief history. In : Thompson T, Dews PB, eds. Advances in behavioral pharmacology. New York : Academic Press, 1977 229 257.
14. Seeman P, Ulpian C. Dopamine D1 and D2 receptor selectivities of agonists and antagonists. Adv Exp Med Biol 1988 235 : 55 63.
15. Lowe JA III., Seeger TF, Vinick FJ. Atypical antipsychotics - recent findings and new perspectives. Med Res Rev 1988 8 : 475 497.
16. Ogren SO, Hogberg T. Novel dopamine-D-2 antagonists for the treatment of schizophrenia. ISI Atlas Sci Pharmacol 1988 2 : 141 147.
17. Jenner P, Marsden CD. The substituted benzamides - a novel class of dopamine antagonists. Life Sci 1979 25 : 479 485.
18. Rich TD. Sulpiride: Assessment of a pharmacologically and chemically distinct neuroleptic. Med Hypotheses 1984 14 : 69 81.
19. Hogberg T. The development of dopamine D2-receptor selective antagonists. Drug Des Discov 1993 9 : 333 350.
20. Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K, Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 1984 102 : 459 474.
21. de Paulis T, Kumar Y, Johansson L, Ramsby S, Florvall L, Hall H, ngeby-Moller K, Ogren SO. Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides. J Med Chem 1985 28 : 1263 1269.
22. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987 1 : 133 152.
23. Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 1980 17 : 385 391.
24. de Paulis T. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain. Curr Pharm Des 2003 9 : 673 696.
25. Casey DE. Extrapyramidal syndromes in nonhuman primates: Typical and atypical neuroleptics. Psychopharmacol Bull 1991b 27 : 47 50.
26. Mohell N, Sallemark M, Rosqvist S, Malmberg A, Hogberg T, Jackson DM. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur J Pharmacol 1993 238 : 121 125.
27. Vartiainen H, Leinonen E, Putkonen A, Lang S, Hagert U, Tolvanen U. A long-term study of remoxipride in chronic schizophrenic patients. Acta Psychiatr Scand 1993 87 : 114 117.
28. Eriksson L. Remoxipride in the treatment of psychoses. Prog Neuropsychopharmacol Biol Psychiatry 1994 18 : 619 623.
29. Keks NA, Burrows GD. Withdrawal of remoxipride. Med J Aust 1994 160 : 591.
30. Philpott NJ, Marsh JC, Gordon-Smith EC, Bolton JS. Aplastic anaemia and remoxipride. Lancet 1993 342 : 1244 1245.
31. de Paulis T, Kumar Y, Johansson L, Ramsby S, Hall H, Sallemark M, ngeby-Moller K, Ogren SO. Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides. J Med Chem 1986 29 : 61 69.
32. Wagner A, Stensland B, Csoregh I, de Paulis T. Molecular structure and absolute configuration of the hydrochloride of a novel dopamine receptor antagonist: 2S(-)-5-chloro-3-ethyl-N-[(1-ethyl-2-pyrrolidinyl) methyl]-6-methoxysalicylamide. Acta Pharm Suec 1985 22 : 101 110.
33. de Paulis T, Hall H, Ogren SO, Wagner A. Synthesis, crystal structure and antidopaminergic properties of eticlopride (FLB 131). Eur J Med Chem 1985 29 : 273 276.
34. Blaton NM, Peeters OM, De Ranter CJ. Cryst Struct Comm 1981 10 : 833.
35. Carnmalm B, Johansson L, Ramsby S, Stjernstrom NE, Wagner A. Absolute configuration of potentially neuroleptic rigid spiro amines. A study on the topography of the neuroleptic receptor. Acta Pharm Suec 1979 16 : 239 246.
36. Tsai RS, Carrupt P-A, Testa B, Gaillard P, El Tayar N. Effects of solvation on the ionization and conformation of raclopride and other antidopaminergic 6-methoxysalicylamides: Insight into pharmacophore. J Med Chem 1993 36 : 196 204.
37. Bouchard G, Pagliara A, Carrupt P-A, Testa B, Gobry V, Girault HH. Theoreical and experimental exploration of the lipophilicity of zwitterionic drugs in the 1,2-dichloroethane/water system. Pharmaceut Res 2002 19 : 1150 1159.
38. 1H-NMR) parameters. Eur J Med Chem 1989 24 : 163 169.
39. Norinder U, Hogberg T. QSAR on substituted salicylamides. In : Fauchere JL, ed. QSAR: Quantitative struture-activity relationships in drug design. New York : Alan R. Liss, Inc, 1989 369 372.
40. de Paulis T, El Tayar N, Carrupt PA, Testa B, vande Waterbeemd H. Quantitative structure-activity relationships of dopamine D2 receptor antagonists: A comparison between orthopramides and 6-methoxysalicylamides. Helv Chem Acta 1991 74 : 241 254.
41. Costall B, Naylor RJ. The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour. Eur J Pharmacol 1973 24 : 8 24.
42. Costall B, Naylor RJ. The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur J Pharmacol 1975 32 : 87 92.
43. Cools ER, Honig WMM, Pijneburg AJJ, Van Rossum JM. The nucleus accumbens of rats and dopaminergic mechanisms regulating locomotor behaviour. Neurosci Lett 1976 3 : 335.
44. Pijnenburg AJ, Honig WM, Van Der Heyden JA, Van Rossum JM. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 1976 35 : 45 58.
45. Ljungberg T, Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action. Psychopharmacology (Berl) 1978 56 : 239 247.
46. Florvall L, Ogren SO. Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities. J Med Chem 1982 25 : 1280 1286.
47. Kohler C, Ogren SO, Haglund L, Angeby T. Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors. Neurosci Lett 1979 13 : 51 56.
48. Hogberg T, Ramsby S, Ogren SO, Norinder U. New selective dopamine D-2 antagonists as antipsychotic agents. Pharmacological, chemical, structural and theoretical considerations. Acta Pharm Suec 1987 24 : 289 328.
49. Ogren SO, Hall H, Widman M, Angeby-Moller K. Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat. Pharmacol Toxicol 1993 73 : 325 334.
50. Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology 1988 94 : 1 7.
51. Kebabian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor". Proc Natl Acad Sci U S A 1972 69 : 2145 2149.
52. Clement-Cormier YC, Kebabian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in mammalian brain: A possible site of action of antipsychotic drugs. Proc Natl Acad Sci U S A 1974 71 : 1113 1117.
53. Karobath M, Leitich H. Antipsychotic drugs and dopamine-stimulated adenylate cyclase prepared from corpus striatum of rat brain. Proc Natl Acad Sci U S A 1974 71 : 2915 2918.
54. Iversen LL. Dopamine receptors in the brain: A dopamine-sensitive adenylate cyclase models synaptic receptors, illuminating antipsychotic drug action. Science 1975 188 : 1084 1089.
55. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990 347 : 146 151.
56. Giros B, Martres MP, Sokoloff P, Schwartz JC. Gene cloning of human dopaminergic D3 receptor and identification of its chromosome. C R Acad Sci III 1990 311 : 501 508.
57. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res 1991 564 : 203 219.
58. Murray AM, Ryoo HL, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A 1994 91 : 11271 11275.
59. List SJ, Wreggett KA, Seeman P. Striatal binding of 2-amino-6,7-[3H] dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics. J Neurosci 1982 2 : 895 906.
60. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980 32 : 229 313.
61. Creese I, Sibley DR, Hamblin MW, Leff SE. The classification of dopamine receptors: Relationship to radioligand binding. Annu Rev Neurosci 1983 6 : 43 71.
62. Creese I, Snyder SH. Dopamine receptor binding of 3H-ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) regulated by guanyl nucleotides. Eur J Pharmacol 1978 50 : 459 461.
63. Seeman P, Woodruff GN, Poat JA. Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors. Eur J Pharmacol 1979 55 : 137 142.
64. Thal L, Creese I, Snyder SH. 3H-Apomorphine interactions with dopamine receptors in calf brain. Eur J Pharmacol 1978 49 : 295 299.
65. Creese I, Padgett L, Fazzini E, Lopez F. 3H-N-n-propylnorapomorphine: A novel agonist ligand for central dopamine receptors. Eur J Pharmacol 1979 56 : 411 412.
66. Titeler M, Seeman P. Selective labelling of different dopamine receptors by a new agonist 3H-ligand: 3H-N-propylnorapomorphine. Eur J Pharmacol 1979 56 : 291 292.
67. Hall H, Kohler C, Gawell L. Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain. Eur J Pharmacol 1985 111 : 191 199.
68. Baldessarini RJ, Kula NS, McGrath CR, Bakthavachalam V, Kebabian JW, Neumeyer JL. Isomeric selectivity at dopamine D3 receptors. Eur J Pharmacol 1993 239 : 269 270.
69. Damsma G, Bottema T, Westerink BH, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wikstrom H. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol 1993 249 : R9-10.
70. Griffon N, Pilon C, Sautel F, Schwartz JC, Sokoloff P. Antipsychotics with inverse agonist activity at the dopamine D3 receptor. J Neural Transm 1996 103 : 1163 1175.
71. Giuliani D, Ferrari F. Involvement of dopamine receptors in the antipsychotic profile of (-) eticlopride. Physiol Behav 1997 61 : 563 567.
72. Tang L, Todd RD, O'Malley KL. Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther 1994 270 : 475 479.
73. Hall H, Sallemark M, Jerning E. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Acta Pharmacol Toxicol (Copenh) 1986 58 : 61 70.
74. Kohler C, Hall H, Gawell L. Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: Evidence for selective labelling of dopamine receptors. Eur J Pharmacol 1986 120 : 217 226.
75. Halldin C, Farde L, Hogberg T, Hall H, Sedvall G. Carbon-11 labelling of eticlopride in two different positions - a selective high-affinity ligand for the study of dopamine D-2 receptors using PET. Int J Rad Appl Instrum [A] 1990 41 : 669 674.
76. Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, Litton JE, Sedvall G. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A 1985 82 : 3863 3867.
77. Kiesewetter DO, Kawai R, Chelliah M, Owens E, McLellan C, Blasberg RG. Preparation and biological evaluation of 18F-labeled benzamide analogs as potential dopamine D2 receptor ligands. Int J Rad Appl Instrum B 1990 17 : 347 356.
78. Halldin C, Farde L, Hogberg T, Hall H, Strom P, Ohlberger A, Solin O. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Int J Rad Appl Instrum B 1991 18 : 871 881.
79. Kessler RM, Ansari MS, de Paulis T, Schmidt DE, Clanton JA, Smith HE, Manning RG, Gillespie D, Ebert MH. High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. J Nucl Med 1991 32 : 1593 1600.
80. Schmidt DE, Votaw JR, Kessler RM, de Paulis T. Aromatic and amine substituent effects on the apparent lipophilicities of N-[(2-pyrrolidinyl) methyl]-substituted benzamides. J Pharm Sci 1994 83 : 305 315.
81. Maeda M, Sasaki S, Fukumura T, Fukuzawa E, Watanabe K, Kojima M, Tahara T, Masuda K, Ichiya Y. Positron-emitting N-[18F]fluoroalkyl and [18F]fluoropyrrolidinyl analogues of eticlopride as potential in vivo radioligands for dopamine D2 receptors. Chem Pharm Bull (Tokyo) 1992 40 : 1793 1798.
82. Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med 2006 47 : 302 312.
83. Magnusson O, Fowler CJ, Kohler C, Ogren SO. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 1986 25 : 187 197.
84. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963 20 : 140 144.
85. Westerink BHC. The effects of drugs on dopamine biosynthesis and metabolism in the brain. In : Horn AS, Korf J, Westerink BHC, eds. The neurobiology of dopamine. London : Academic Press, 1979 255 291.
86. Masserano JM, Weiner N. Tyrosine hydroxylase regulation in the central nervous system. Mol Cell Biochem 1983 5-5 : 129 152.
87. Tang L, Todd RD, Heller A, O'Malley KL. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 1994 268 : 495 502.
88. Chio CL, Lajiness ME, Huff RM. Activation of heterologously expressed D3 dopamine receptors: Comparison with D2 dopamine receptors. Mol Pharmacol 1994 45 : 51 60.
89. Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988 336 : 783 787.
90. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991 350 : 610 614.
91. Swarzenski BC, Tang L, Oh YJ, O'Malley KL, Todd RD. Morphogenic potentials of D2, D3, and D4 dopamine receptors revealed in transfected neuronal cell lines. Proc Natl Acad Sci U S A 1994 91 : 649 653.
92. Pilgrim C, Stumpf WE. Applications of autoradiography in neurobiological research. J Histochem Cytochem 1987 35 : 917 928.
93. Kohler C, Radesater AC. Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride. Neurosci Lett 1986 66 : 85 90.
94. Hall H, Farde L, Halldin C, Hurd YL, Pauli S, Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 1996 23 : 115 123.
95. Snyder SH, Creese I, Burt DR. The brain's dopamine receptor: Labeling with (3H) dopamine and (3H) haloperidol. Psychopharmacol Commun 1975 1 : 663 673.
96. Bracha HS, Kleinman JE. Postmortem neurochemistry in schizophrenia. Psychiatr Clin North Am 1986 9 : 133 141.
97. Kleinman JE, Casanova MF, Jaskiw GE. The neuropathology of schizophrenia. Schizophr Bull 1988 14 : 209 216.
98. Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 1995 346 : 743 749.
99. Bergman J, Kamien JB, Spealman RD. Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav Pharmacol 1990 1 : 355 363.
100. Nader MA, Green KL, Luedtke RR, Mach RH. The effects of benzamide analogues on cocaine self-administration in rhesus monkeys. Psychopharmacology 1999 147 : 143 152.
101. Winger G. Dopamine antagonist effects on behavior maintained by cocaine and alfentanil in rhesus monkeys. Behav Pharmacol 1994 5 : 141 152.
102. Ellenbroek BA, Cools AR. Animal models with construct validity for schizophrenia. Behav Pharmacol 1990 1 : 469 490.
103. Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000 11 : 223 233.
104. Pawlowski J, Kmieciak-Kolada K, Ouchowicz E, Krysiak R, Herman ZS. Effect of substituted benzamides on feeding and hypothalamic neuropeptide Y-like immunoreactivity (NPY-LI) in rats. Neuropeptides 2001 35 : 204 210.
105. LaHoste GJ, Marshall JF. Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: Autoradiographic evidence against the dual mechanism hypothesis. Neuroscience 1991 41 : 473 481.
106. Czoty PW, Gage HD, Nader MA. PET imaging of striatal dopamine D2 receptors in nonhuman primates: Increases in availability produced by chronic raclopride treatment. Synapse 2005 58 : 215 219.
107. Macht DI. Effect of sulfonamides on cerebral and neuromuscular actions. Exp Med Surgery 1943 1 : 260 272.
108. Sidman M. Avodiance condioning with brief shock and no exteroceptive warning signal. Science 1953 118 : 157 158.
109. Cook L, Weidley EF, Morris RW, Mattis PA. Neuropharmacological and behavioral effectgs of "Thorazine" hydrochloride (chlorpromazine). J Pharmacol Exp Ther 1955 113 : 11 12.
110. Kuribara H, Tadokoro S. Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav 1981 14 : 181 192.
111. White IM, Rebec GV. Performance on a lever-release, conditioned avoidance response task involves both dopamine D1 and D2 receptors. Eur J Pharmacol 1994 253 : 167 169.
112. White IM, Ciancone MT, Haracz JL, Rebec GV. A lever-release version of the conditioned avoidance response paradigm: Effects of haloperidol, clozapaine, sulpiride, and BMY-14802. Pharmacol Biochem Behav 1991 41 : 29 35.
113. Ferrari F, Giuliani D. Behavioural assessment in rats of the antipsychotic potential of the potent dopamine D2 receptor antagonist, (-)eticlopride. Pharmacol Res 1995 31 : 261 267.
114. Sanberg PR, Pisa M, Faulks IJ, Fibiger HC. Experimental influences on catalepsy. Psychopharmacology 1980 69 : 225 226.
115. Fowler SC, Skjoldageer PD, Liao R-M, Chase JM, Johnson JS. Distinguishing between haloperidol's and decamethonium's disruptive effects on operant behavior in rats: Use of measurements that complement response rate. J Exp Anal Behav 1991 56 : 239 260.
116. Fowler SC, Liou J-R. Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not. Psychopharmacology 1998 140 : 81 90.
117. Guarraci FA, Frohardt RJ, Falls WA, Kapp BS. The effects of intra-amygdaloid infusions of a D2 dopamine receptor antagonist on Pavlovian fear conditioning. Behav Neurosci 2000 114 : 647 651.
118. Smith AD, Smith DL, Zigmond MJ, Amalric M, Koob GF. Differential effects of dopamine receptor subtype blockade on performance of rats in a reaction-time paradigm. Psychopharmacology 2000 148 : 355 360.
119. 2-receptor blocker, in acute schizophrenia: An open trial. Int Clin Psychopharmacol 1989 4 : 61 70.
120. Casey DE. A double blind multicentre trial comparing raclopride and haloperidol in schizophrenia. Biol Psychiatry 1991 2 9 (Suppl 645.
121. McCreadie RG. A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. Acta Psychiatr Scand 1992 86 : 391 398.
122. McEvoy JP, Movin-Osswald G, Uppfeldt G, Williams T, Dutcher S, Apperson J. An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients. Psychopharmacol 1993 112 : 371 374.
123. Gendron A, Sirois G, Nair NPV, Bloom D, Movin-Osswald G, Uppfeldt G. An open study of the tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: A Canadian study. J Psychiatry Neurosci 1995 20 : 287 296.
124. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006 63 : 679 685.
125. Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: Unexpected differences between rodents and primates. Trends Neurosci 1991 14 : 21 27.
126. Joel D, Weiner I. The connections of dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000 96 : 451 474.